Bristol/Sano transdermal BuSpar alliance to market anti-anxiety patch.
Executive Summary
BRISTOL/SANO BUSPAR TRANSDERMAL PATCH SNDA FILING EXPECTED IN 1997 for the treatment of anxiety, Sano indicated. Bristol-Myers Squibb and Sano announced an exclusive worldwide alliance to complete clinical testing and to market Sano's transdermal formulation of Bristol-Myers Squibb's anti-anxiety drug BuSpar (buspirone) Aug. 20. Transdermal buspirone could be on the market as soon as 1998, Sano predicted. The buspirone patch is in Phase III trials for the treatment of anxiety and depression and in Phase II trials for attention-deficit disorder.